That was my disappointment in yesterday's call. It would have been great to have a "we are hitting the ground running" plan presented. I would have been thrilled to know the funding was in place as well. I know it is a relatively inexpensive study but there is a bit too much of this talk happening for my liking:

13:28: The challenge of course is that CytoDyn is just emerging from a (2) year clinical hold and doesn't have the resources to do everything we would like. We are also keenly aware of the need to stay focused and not trying to do too much all at once. With that said, the Board and Management are working closely together to identify our priorities and the appropriate next steps to proceed. To that end, we will be taking steps to ensure the effective and efficient use of our resources while incorporating funding through 3rd party sources wherever possible. To be clear, we will be prioritizing opportunistic ways to develop and create value through various means for leronlimab and employing strategies that are time and cost effective including for example, opportunities through non-dilutive funding, license agreements, co-development initiatives and partnerships.